Literature DB >> 8208061

Neurokinin receptor subtypes characterized by biological assays.

D Regoli1, Q T Nguyen, D Jukic.   

Abstract

Neurokinin receptors have been characterized by biological assays using naturally occurring and selective agonists as well as peptide and non peptide antagonists. Six preparations have been used: the rabbit vena cava and the rat urinary bladder, treated with a NK-2 receptor antagonist for the NK-1 receptor, the rabbit pulmonary artery and the hamster urinary bladder for the NK-2, the rat portal vein and the guinea pig ileum, treated with a NK-1 receptor antagonist, for the NK-3. Treatment with antagonists was required because of the presence (in some preparations) of two functional sites contributing to the biological effect. Differences in the order of potency of agonists between each couple of receptors have been demonstrated, especially with tachykinins and the selective agonists. Such differences are even more evident with antagonists, some of which show apparent affinity (pA2) values 1.5 to 3 log units higher in one than in the other member of each couple. Based on data obtained in pharmacological experiments, it is concluded that NK-1, NK-2 and NK-3 receptors show differences strong enough to justify the assumption that their coding and/or expression diverge among species.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8208061     DOI: 10.1016/0024-3205(94)00712-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  11 in total

1.  Translocation of Bax and Bid to mitochondria, endoplasmic reticulum and nuclear envelope: possible control points in apoptosis.

Authors:  Barbara Gajkowska; Urszula Wojewódzka; Joanna Gajda
Journal:  J Mol Histol       Date:  2004-01       Impact factor: 2.611

2.  Characteristics of substance P transport across the blood-brain barrier.

Authors:  Arvind K Chappa; Kenneth L Audus; Susan M Lunte
Journal:  Pharm Res       Date:  2006-06-01       Impact factor: 4.200

3.  Neurokinins enhance excitability in capsaicin-responsive DRG neurons.

Authors:  Adrian Sculptoreanu; William C de Groat
Journal:  Exp Neurol       Date:  2007-02-14       Impact factor: 5.330

4.  The predicting role of substance P in the neoplastic transformation of the hypoplastic bone marrow.

Authors:  M Nowicki; D Ostalska-Nowicka; A Konwerska; B Miskowiak
Journal:  J Clin Pathol       Date:  2006-09       Impact factor: 3.411

5.  Modulation of cardiac activity by tachykinins in the rat substantia nigra.

Authors:  A Lessard; R Couture
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 6.  Kisspeptins in human reproduction-future therapeutic potential.

Authors:  Kulvinder Kochar Kaur; Gautam Allahbadia; Mandeep Singh
Journal:  J Assist Reprod Genet       Date:  2012-09-27       Impact factor: 3.412

7.  Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study.

Authors:  Andrée Lessard; Maria M Campos; Witold Neugebauer; Réjean Couture
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

8.  Autocrine proliferation of neuroblastoma cells is partly mediated through neurokinin receptors: relevance to bone marrow metastasis.

Authors:  Indroneil Mukerji; Shakti H Ramkissoon; Kavitha K R Reddy; Pranela Rameshwar
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

9.  Accelerated onset of the vesicovesical reflex in postnatal NGF-OE mice and the role of neuropeptides.

Authors:  Beatrice Girard; Abbey Peterson; Susan Malley; Margaret A Vizzard
Journal:  Exp Neurol       Date:  2016-06-21       Impact factor: 5.330

10.  Tachykinins and tachykinin receptors in human uterus.

Authors:  Eva Patak; M Luz Candenas; Jocelyn N Pennefather; Sebastian Ziccone; Alison Lilley; Julio D Martín; Carlos Flores; Antonio G Mantecón; Margot E Story; Francisco M Pinto
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.